TL;DR - On July 27, 2026, Johnson & Johnson announced a proposed resolution of the ovarian cancer talc litigation covering about 76,000 claims in the federal MDL and related state courts. - J&J put the value at about $5.5 billion. Lead plaintiffs' counsel describe the deal as uncapped, with a minimum of $5.8 billion. - The proposal depends on lead plaintiff firms representing at least 95% of the claims agreeing to participate. - Mesothelioma claims are not part of the proposal.
What was announced
Johnson & Johnson announced a proposed settlement of the ovarian cancer talcum powder claims on July 27, 2026. The proposal covers roughly 76,000 claims pending in MDL No. 2738 in the District of New Jersey (Judge Michael A. Shipp) and in related state-court proceedings. As of September 1, 2026, 69,250 cases were pending in the MDL, about a third of all cases in federal multidistrict litigation.
J&J's announcement described a resolution of about $5.5 billion. A release from plaintiffs' counsel at Seeger Weiss dated July 28 described the agreement as "uncapped" and said J&J would pay a minimum of $5.8 billion, with compensation distributed through a tiered grid based on objective criteria. The two descriptions have not been reconciled publicly, and the final terms will come from the settlement documents themselves.
Conditions and timing
The proposal is conditioned on participation by lead plaintiff firms representing at least 95% of the covered claims. Reported terms include a first payment of no more than $3 billion in 2027. Claimants represented by counsel should contact their law firm about enrollment deadlines, because those deadlines had not been published in the materials reviewed for this article.
How the settlement came about
The announcement followed a difficult stretch for the plaintiffs. In January 2026, special master and retired Judge Freda Wolfson found that plaintiffs' general causation experts met federal admissibility standards. After a May 2026 evidentiary hearing, however, plaintiffs withdrew their specific-causation experts in two bellwether cases, and J&J asked the court to dismiss the remaining ovarian cancer claims. A hearing on how plaintiffs would proceed was held on August 3, 2026, after the settlement announcement.
The deal also follows J&J's three unsuccessful attempts to resolve talc claims through bankruptcy, and a run of large state-court verdicts, including a $1.56 billion verdict in Baltimore in February 2026.
What it does not cover
Mesothelioma claims are not part of this proposal and continue to be litigated separately. State-court trials may also continue for claims that are not resolved through the program.
What claimants should know
A proposed settlement is not a final one. Payment amounts depend on the grid, the claimant's documented diagnosis and exposure, and the participation threshold being met. Past settlement amounts do not guarantee any individual outcome. Anyone who used talc products and was diagnosed with ovarian cancer should speak with a licensed attorney about their specific situation.
For the full litigation history, see our talcum powder case guide.
The information on mass-torts.com is for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by using this website. Laws vary by state and jurisdiction. For advice about your specific situation, consult a licensed attorney in your jurisdiction. mass-torts.com is not a law firm and does not provide legal representation.